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Nitric oxidea b s t r a c t
In this study, a series of synthesized 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives
as a potential antiproliferative and antimigratory agents were investigated. The possible antitumor mech-
anisms of investigated hydantoin derivatives were examined on human breast cancer cell line MDA-MB-
231. The cells were treated with different concentrations of compounds (from 0.01 mM to 100 mM) during
24 h and 72 h. The proliferation index, nitric oxide production, apoptosis rate, and migration capacity
were measured. The cell invasion potential was examined by measuring the level of MMP-9 and COX-
2 gene expression. All tested compounds expressed antiproliferative activity and induced dose- and
time-dependent increase in the level of nitrites. The investigated molecules significantly decreased cell
survival rate, migration capacity and the expression levels of genes included in the process of tumor inva-
sion. Obtained data suggest that the tested hydantoin derivatives express considerable antitumor activity
by reducing cell division rate, elevating apoptosis level, and inhibiting the motility and invasiveness of
breast cancer cells. The results obtained in this study indicate that investigated compounds express
potential as a novel chemotherapeutic agents against breast cancer growth and progression.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction human breast carcinoma (Gomha et al., 2016, Tao et al., 2018,Breast cancer is the most common cancer type and the second
leading cause of cancer-related deaths in women across the world
resulting in more than half a million deaths each year (Murad et al.,
2016). Despite the extensive use of multimodal chemotherapies,
the level of mortality remains high, emphasizing the need for novel
therapeutic approaches with higher efficiency against malignant
cells and advanced selectivity towards healthy tissues. Some stud-
ies showed that different heterocyclic compounds containing
nitrogen atom exhibit significant antiproliferative activity againstGomha et al., 2018).
Derivatives of hydantoin are commonly used for clinical treat-
ment of epilepsy and cardiac arrhythmias (Herrera et al., 2015,
Kumkamthornkul et al., 2018), but various additional properties
of hydantoins such as anti-inflammatory and antitumor activities
have also been noticed (Trišović et al., 2011, Obradović et al.,
2013, Marinova et al., 2016, Obradović et al., 2019). One of the
most prominent antitumor roles of hydantoin compounds is their
significant antiproliferative potential exerted against different
types of cancer cells (Cavazzoni et al., 2008, Zuliani et al., 2009,
Sekulić Djaković et al., 2015). Certain, hydantoin derivatives have
been shown to display strong cytotoxicity in breast cancer cells
and induce growth inhibition and apoptosis (Rajic et al., 2006).
Moreover, hydantoin core ring variations can be found as a moiety
in many drugs used in chemotherapy. Thus selenohydantoins,
derivatives of hydantoins in which one of the oxygen atoms is
replaced by selenium, express the strong antitumor activity and
can be used as effective antioxidants (Ivanenkov et al., 2016).
Beside uncontrolled proliferation, cancer cells display signifi-
cant migratory and invasive potential which inducing metastasis.
Fig. 1. Structures of investigated compounds.
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sion, and dissemination. Tumor-associated inflammation initially
promotes tumor growth and stimulates cancer cell survival, but
it also enhances metastatic potential of the tumor. Cyclooxygenase
2 (COX-2) is often overexpressed in breast cancer cells (Chow et al.,
2008). Although the use of non-steroidal anti-inflammatory drugs
(NSAIDs) are associated with reduced risk of cancer overall and
breast cancer in particular (Bowers et al., 2014), their detrimental
side effects have been recorded due to low selectivity (Bundred
and Barnes, 2005). The usage of new selective COX-2 inhibitors
could provide satisfying anti-inflammatory effects and devoid of
undesirable effects associated with classical, non-selective NSAIDs.
Some recent studies are suggesting a prominent place of selective
COX-2 inhibitors in the prevention of different tumors including
breast cancer (Mazhar et al., 2005, Takkouche et al. 2008,
Regulski et al., 2016).
Extracellular proteinases are essential for metastasis since these
enzymes degrade the components of the extracellular matrix and
facilitate the disruption of intercellular adhesions, separating indi-
vidual cells from solid tumor tissue (Herszényi et al., 2014). Among
the matrix metalloproteinase family (MMPs), MMP-9 is known to
be significantly upregulated in almost all tumor types, including
breast cancer (Taguchi et al., 2014). Furthermore, MMP-9 expres-
sion positively correlates with cancer stage, grade and prognosis,
making it a convenient marker, and a potential therapeutic target
for preventing the invasion and metastasis of breast cancer (Roy
et al., 2009, Alaseem et al., 2019).
Nitric oxide (NO) has also been considered a tumor-associated
molecule. The roles of NO in tumor formation and progression
remain controversial. This molecule has an important role in vari-
ous stages of tumorigenesis such as DNA damage, oncogene activa-
tion, inhibition of DNA repair enzymes and tumor suppressor
genes, and the modulation of apoptosis and metastasis (Fionda
et al., 2016). The different roles of NO in apoptosis, cell cycle, tumor
progression, angiogenesis, and metastasis are currently viewed at
host tissue and tumor interface since NO was found to be strikingly
associated with tumor parenchyma, as well as with the tumor
microenvironment (Vannini et al., 2015). The tumor microenviron-
ment includes the cells of the immune system and vascular tissue,
and NO appears to be one of the key components of their activity
(Artacho-Cordón et al., 2012). Antitumor effects of NO were also
recorded in different human and animal tumors (Choudhari
et al., 2013, Vahora et al., 2016). iNOS overexpression induces sim-
ulative or inhibitory effects on tumor growth, depending on the
microenvironment and tumor type (Mocellin et al., 2007). Overall,
the effect of NO depends on the expression level of iNOS, duration
and timing of NO delivery, contents of the microenvironment,
genetic background, and type of cell, but undoubtedly is involved
in tumor progression (Vannini et al., 2015). The increasing data
which indicate hydantoins antitumor activity suggest a beneficial
role of these compounds in developing of novel chemotherapeu-
tics. Accordingly, the aim of this research was to evaluate the
effects of seven 3-(4-substitutedbenzyl)-5-isopropyl-5-phenylhy
dantoin derivatives (1–7, Fig. 1.) on survival ratio, type of cell
death, proliferation level, NO production rate, COX-2 and MMP-9
expression profile, and migration/invasion capacity of human
breast cancer cell line, MDA-MB-231.2. Materials and methods
2.1. Cell cultivation and treatment
The human breast cancer cell line MDA-MB-231 line was
obtained from American Tissue Culture Collection. These cells were
propagated and maintained in DMEM (Dulbecco’s Modified EagleMedium, SIGMA-ALDRICH, USA) and supplemented with 10% Fetal
Bovine Serum (FBS, SIGMA-ALDRICH, USA) and antibiotics (peni-
cillin (100 IU/mL) and streptomycin (100 mg/mL). After several pas-
sages the cells were trypsinized, seeded in 96-well plate (104 cells
per well) and cultured in a humidified atmosphere with 5% CO2 at
37 C.
After 24 h of incubation, 100 lL of working solution (concentra-
tion range: 0.01 lM  100 lM) was added. Stock solutions of the
compounds were made in dimethyl sulfoxide (DMSO) at the con-
centration of 1 M and diluted with DMEM to various working con-
centrations. The concentration of DMSO in the most concentrated
working solutions was 0.01% (v/v).
2.2. Determination of cell viability
The cells were treated with various doses (0.01 lM, 0.1 lM,
1 lM, 10 lM, 50 lM, and 100 lM) of the investigated compounds
for 24 h and 72 h. Non-treated cells served as control. After treat-
ment, cell proliferation was determined by the MTT assay
(Mosmann, 1983). At the end of the treatment period, 25 lL of
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, SIGMA-ALDRICH, USA) solution (5 mg/mL final concentra-
tion in PBS (GIBCO, Invitrogen, USA)) was added to each well and
incubated in a humidified atmosphere with 5% CO2 at 37 C for
three hours. The produced formazan was dissolved by overnight
incubation in SDS-HCl (10% SDS in 0.01 M HCl) and the percentage
of viable cells was calculated as the ratio between the absorbance
at each dose of the compounds and the absorbance of the
untreated control multiplied by 100 to get a percentage. The absor-
bance was measured at 550 nm on ELISA (2100C) 96-well plate
reader (Rayto, China). We also calculated the half-maximal inhibi-
tory concentration (IC50), defined as the concentration of tested
hydantoin derivatives that inhibited cell growth by 50% compared
to control. All experiments were performed in triplicate. The IC50
values were calculated from the dose curves by the software
CalcuSyn.
2.3. Determination of type of cell death
Apoptosis and necrosis were analyzed by double staining with
annexin V-FITC and 7-AAD. Annexin V binds to the cells with
exposed phosphatidylserine, whereas 7-AAD labels the cells with
membrane damage. Apoptotic cells were detected using the
Annexin V-FITC/7-AAD Kit (Apoptosis Detection Kit, Beckman
Coulter, USA). Staining was performed according to the manufac-
turer’s instructions and Shounan protocol (Shounan et al., 1998).
After the treatment with compounds 0, 3, and 4 (Fig. 1.) at a con-
centration of 1 lM and 10 lM, the cells were collected, washed
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events were analyzed on FC500 Beckman Coulter Flow Cytometer
(Nyon, Switzerland). The percent of viable (Annexin V7-AAD-)
cells, early apoptotic (Annexin V+7-AAD-) cells, late apoptotic
(Annexin V+7-AAD+) cells, and necrotic cells (Annexin V7-AAD+)
cells were evaluated by Flowing Software (http://www.flowing-
software.com/).
2.4. Caspase activation
The activity of caspases, the enzymes involved in the execution
of apoptosis, was measured by flow cytometry after labeling the
cells with a cell-permeable FITC-conjugated pan-caspase inhibitor
(ApoStat; R&D Systems, Minneapolis, MN) according to the manu-
facturer’s instructions. The increase in green fluorescence (FL1), as
a measure of caspase activity, was determined using FACSCalibur
flow cytometer (BD Biosciences, Germany), and the results were
expressed as the percentage (%) of cells with active caspases.
2.5. Determination of NO production
The spectrophotometric determination of nitrites - NO2– (an
indicator of the nitric oxide level) was performed by using the
Griess method (Griess, 1879). Griess reaction is based on the cou-
pling of NO-generated diazonium ion with N-(1-napthyl) ethylene-
diamine where a chromophoric azo product is formed with an
absorption maximum at 550 nm and measured by ELISA micro-
plate reader. The concentrations of nitrites were calculated from
the appropriate standard curves for nitrites.
2.6. Cell migration
The cell migration capacity was determined by measuring the
ability of cells to pass the pores of polycarbonate membranes (pore
size 8 mm; Greiner Bio-One, Switzerland) at the bottom of tran-
swell chambers. The migration test was performed according to
the protocol described by Chen (Chen, 2005). The cells were
exposed to 1 lM and 10 lM concentration of compounds 0, 3,
and 4 for 24 h and 72 h, respectively. The control cells were cul-
tured only in DMEM. After the treatments, all groups of treated
cells were trypsinized and placed in the upper chambers at a den-
sity of 1  105 cells/well in 500 mL of DMEM with 10% FBS. The
lower chambers contained 750 mL of DMEM supplemented with
10% FBS. After 6 h of incubation at 37 C, the cells from the upper
surface of the membrane were completely removed with gentle
swabbing. The remaining migrated cells were fixed for 20 min at
room temperature in 4% paraformaldehyde and stained with 0.1%
crystal violet in 200 mM 2-(N-Morpholino) ethanesulfonic acid
(pH 6.0) for 10 min. Absorbance was measured by a microplate
reader at 595 nm. The migration index was calculated as the ratio
of absorbance of the treated cells divided by the absorbance of the
control cells and multiplied by 100 to give the percentage.
2.7. Quantitative PCR (qPCR)
Total cell RNA was isolated from cells using TRIzol reagent
according to Chomczynski and Sacchi protocol (Chomczynski and
Sacchi, 1987). The purity and concentrations of obtained RNA were
evaluated spectrophotometrically by measuring solution absor-
bance at 260 and 280 nm. The A260/A280 ratio of the samples
was  1.8. Extracted RNA (2 mg) from each sample were reversely
transcribed using Superscript II RT enzyme (Invitrogen) in a total
reaction volume of 20 mL. The obtained complementary DNA
(cDNA) was PCR-amplified and the final 20 mL reaction volume
contained 0.5 mM primers, 1  SYBR Green PCR Master Mix
(Applied Biosystems) and 2 mL of the cDNA. cDNA amplificationwas performed by qRT-PCR method (quantitative real-time PCR)
in 7500 Real Time System (Thermo Fisher Scientific) using the pri-
mer pairs (Obradović et al., 2019).
The qPCR reaction program was set in accordance with the
manufacturer’s instructions (Applied Biosystems): activation of
the polymerase for 3 min at 95 C, 40 cycles of 15 sec at 95 C
and 60 sec at 55 C. Relative expression value was calculated
according to formula DCT - DDCT where DCT refers to the differ-
ence between the cycle threshold values (CT) obtained for the tar-
get gene in treatment sample and non-treated control,
respectively, and DDCT represents the difference of b-actin gene
expression levels (endogenous control) (Livak and Schmittgen,
2001). The negative control samples (without cDNA) were also
amplified in qPCR reaction to confirm that the contamination with
genomic DNA was in the acceptable range (Cheeseman et al.,
2012). The results were expressed as the percentage of the change
compared to control values.
2.8. Statistical analysis
All values are expressed as mean ± SE. Statistical evaluation was
calculated by Paired Sample T-Test, SPSS. The magnitude of the
correlation between variables was done using an SPSS (Chicago,
IL) statistical software package (SPSS for Windows, ver. 17). For
all comparisons p < 0.05 control vs. treatment was considered sig-
nificant. The data are the result of three independent (individual)
experiments, performed in triplicate for each dose.3. Results
3.1. Antiproliferative potential of isopropyl-phenyl hydantoins
At our previous research (Trišović et al., 2011, Obradović et al.,
2013) compound 3-benzyl-5,5-diphenylhydantoins, marked as
compound 0, showed the strongest activity in the previously tested
hydantoin derivatives series. Accordingly, this compound was used
for comparison of the effects with the new series of isopropyl-
phenyl hydantoins. In Tables 1 and 2 antiproliferative effects of
these compounds at various concentrations on the human breast
cancer cell line, MDA-MB-231, after 24 and 72 h of incubation
are presented. All compounds showed significant antiproliferative
activities on MDA-MB-231 cells compared to non-treated cells.
All compounds showed considerable dose- and time-dependent
inhibition of MDA-MB-231 cell proliferation. Antiproliferative
activity of compound 3 was the highest after 24 h treatment and
compound 4 showed the strongest effects after 72 h.
Since the compounds used in this study show significant
antiproliferative effects on MDA-MB-231 cells, these molecules
should be further investigated for the mechanisms of their antipro-
liferative action. The results of the antiproliferative activity of all
investigated compounds on MDA-MB-231 cells were expressed
as IC50 values and presented in Table 3. After 72 h treatment, all
examined compounds showed stronger antiproliferative activity
compared to short-term (24 h) treatment. After long-term treat-
ment, all compounds showed higher antiproliferative potential
compared to compound 0, from the previous study, with IC50 val-
ues<10 mM, except for the compound 1.
3.2. Determination of cell apoptosis by Annexin V-FITC/7-AAD staining
The type of cell death induced by treatment with investigated
hydantoin derivatives was determined by flow cytometric analysis
of treated cells stained with Annexin V FITC and 7-AAD. The stron-
gest antiproliferative effect has been exerted by compound 3 and 4,
and the effect was significantly stronger compared to compound 0,
Table 1
Effect of investigated compounds on proliferation index of MDA-MB-231 cells expressed as percentage of proliferation level after 24 h compared to non-treated control cells
(100%).
No 0.01 mM 0.1 mM 1 mM 10 mM 50 mM 100 mM
0 85 ± 3.8 * 75 ± 3.6* 72 ± 1.1 * 69 ± 2.9 * 53 ± 1.8 * 42 ± 2.3 *
1 82 ± 2.8 * 78 ± 2.0 * 75 ± 1.0 * 68 ± 2.6 * 73 ± 4.8 * 57 ± 4.3 *
2 84 ± 2.3 * 70 ± 5.1 * 75 ± 4.1 * 70 ± 4.2 * 57 ± 6.0 * 53 ± 6.9 *
3 81 ± 1.2 * 68 ± 3.2 * 67 ± 2.6 * 65 ± 4.9 * 56 ± 1.2 * 40 ± 2.1 *
4 83 ± 1.8 * 75 ± 2.4 * 60 ± 4.6 * 58 ± 4.8 * 46 ± 2.4 * 41 ± 3.3 *
5 78 ± 2.2 * 68 ± 2.8 * 70 ± 3.5 * 67 ± 3.3 * 61 ± 2.1 * 56 ± 2.4 *
6 87 ± 1.5 * 77 ± 3.7 * 66 ± 2.4 * 64 ± 3.6 * 53 ± 4.8 * 45 ± 3.2 *
7 79 ± 2.0 * 70 ± 2.7 * 76 ± 2.4 * 71 ± 1.4 * 56 ± 3.0 * 44 ± 4.6 *
The results are expressed as the mean ± SE from three independent experiments performed in triplicate. (*p < 0.05 different concentrations of compound vs. control)
Table 2
Effect of investigated compounds on proliferation index of MDA-MB-231 cells expressed as percentage of proliferation level after 72 h compared to non-treated control cells
(100%).
No 0.01 mM 0.1 mM 1 mM 10 mM 50 mM 100 mM
0 79 ± 1.2 * 65 ± 3.3 * 58 ± 3.0 * 52 ± 1.7 * 50 ± 3.9 * 39 ± 2.8 *
1 71 ± 4.2 * 70 ± 3.3 * 60 ± 4.0 * 50 ± 2.7 * 49 ± 2.8 * 55 ± 1.8 *
2 63 ± 3.6 * 60 ± 1.2 * 59 ± 3.7 * 56 ± 4.2 * 45 ± 1.3 * 40 ± 2.7 *
3 70 ± 1.9 * 65 ± 1.3 * 55 ± 4.30 * 50 ± 1.1 * 45 ± 3.1 * 32 ± 5.8 *
4 60 ± 3.7 * 57 ± 3.3 * 55 ± 2.8 * 49 ± 1.7 * 37 ± 3.1 * 31 ± 2.5 *
5 59 ± 2.0 * 50 ± 2.5 * 46 ± 1.8 * 55 ± 1.6 * 40 ± 2.1 * 38 ± 3.7 *
6 65 ± 9.9 * 55 ± 0.4 * 43 ± 4.9 * 53 ± 8.7 * 42 ± 4.7 * 35 ± 6.0 *
7 68 ± 3.2 * 63 ± 3.8 * 53 ± 4.2 * 45 ± 8.4 * 43 ± 4.3 * 40 ± 4.9 *
The results are expressed as the mean ± SE from three independent experiments performed in triplicate. (*p < 0.05 different concentrations of compound vs. control)
Table 3
The half-maximal inhibitory concentration IC50 (mM) of investigated compounds
against MDA-MB-231 cells proliferation.
No. 24 h 72 h
0 87 ± 0.2 14 ± 0.03
1 > 100 78 ± 0.1
2 > 100 10 ± 0.1
3 74 ± 0.1 6 ± 0.1
4 21 ± 0.2 0.90 ± 0.1
5 > 100 1.40 ± 0.04
6 > 100 1.20 ± 0.1
7 > 100 3.70 ± 0.1
The cells treated with various concentrations of compounds during a 24 and 72 h.
The results are expressed as the mean ± SE from three independent experiments
performed in triplicate.
Fig. 2. Flow cytometric analysis of Annexin V-FITC/7-AAD stained MDA-MB-231
cells for 24 h with compounds 0, 3, and 4 at concentrations 1 mM (A) and 10 mM (B).
The percentages of early apoptotic (Annexin V+7-AAD-, lower right quadrant), late
apoptotic (Annexin V+7-AAD+, upper right quadrant) and necrotic cells (Annexin
V7-AAD+, upper left quadrant) in non-treated and treated cells are indicated on dot
plots). The results are expressed as the mean ± SE from three independent
experiments performed in triplicate. (*p < 0.05 different concentrations of
compound vs. control).
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2011). Subsequently, compounds, 3 and 4, their structure was
shown in Fig. 1, were selected for further research and determining
of the antitumor mechanisms, in concentrations of 1 mM and 10 mM
where the antiproliferative effect is clearly evident. MDA-MB-231
cells were incubated during 24 and 72 h. At both examined con-
centrations, all three compounds induced a statistically significant
increase of apoptosis rate in MDA-MB-231 cells, after 24 h treat-
ment, (shown in Fig. 2), and 72 h treatment (shown on Fig. 3).
The time- and dose-dependent effects of the compounds are
respectively exhibited.3.3. Determination of caspase activation
MDA-MB-231 cells were treated with 1 lM and 10 lM of
selected derivatives 0, 3, and 4 during 24 and 72 h. At both exam-
ined concentrations, all three compounds have stimulated the acti-
vation of the apoptosis executing enzymes, caspases, as
demonstrated by an increase in Apostat fluorescence signal. The
data are shown in Figs. 4 and 5 represent caspases activation.3.4. Determination of NO production by Griess assay
The data shown in Fig. 6 represent nitrite concentrations in
supernatants of MDA-MB-231 cells treated with 1 lM and
10 lM of selected compounds 0, 3, and 4 after 24 and 72 h. All
three compounds showed a significant increase in production of
NO by MDA-MB-231 cells measured by nitrite concentrations com-
pared to NO values in supernatants of non-treated cells. The stron-
gest activity has been shown on compound 3 after 24 h of
Fig. 3. Flow cytometric analysis of Annexin V-FITC/7-AAD stained MDA-MB-231
cells for 72 h exposure with compounds 0, 3, and 4 at concentrations 1 mM (A) and
10 mM (B). The percentages of early apoptotic (Annexin V+7-AAD-, lower right
quadrant), late apoptotic (Annexin V+7-AAD+, upper right quadrant) and necrotic
cells (Annexin V7-AAD+, upper left quadrant) in untreated and treated cells are
indicated on dot plots).The results are expressed as the mean ± SE from three
independent experiments performed in triplicate. (*p < 0.05 different concentra-
tions of compound vs. control).
Fig. 4. The antitumor activity of investigated compounds against MDA-MB-231
cells in vitro after 24 h. MDA-MB-231 cell line were treated with compounds 0, 3,
and 4 at concentrations 1 mM and 10 mM during 24 h exposure compared to non-
treated control cell (100%). The cell viability was determined using caspase
activation by flow cytometry. The results are expressed as the mean ± SE from
three independent experiments performed in triplicate. (*p < 0.05 different
concentrations of compound vs. control).
Fig. 5. The antitumor activity of investigated compounds against MDA-MB-231
cells in vitro after 72 h. MDA-MB-231 cell line were treated with compounds 0, 3,
and 4 at concentrations 1 mM and 10 mM during 72 h exposure compared to non-
treated control cell (100%). The cell viability was determined using caspase
activation by flow cytometry. The results are expressed as the mean ± SE from
three independent experiments performed in triplicate. (*p < 0.05 different
concentrations of compound vs. control).
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strongest effect.
3.5. Expression of the inducible nitrite oxide synthase (iNOS) gene
In Fig. 7, the changes in the iNOS gene expression profile
induced by synthesized hydantoin compounds 0, 3, and 4 are pre-
sented. The results show that long-term treatment (72 h) with all
three hydantoin derivatives at concentrations of 1 mM and 10 mM
caused statistically significant increase in gene expression com-
pared to non-treated cells.
3.6. Migration capacity (Boyden chamber assay)
To examine the effects of hydantoin derivatives on the migra-
tion capacity of human breast cancer cell line MDA-MB-231, the
transwell migration assay was performed. The results presented
in Fig. 8 show a significant decrease in migration index of MDA-
MB-231 cells exposed to compounds 0, 3, and 4 at a concentration
of 1 mM and 10 mM for 24 and 72 h, respectively, compared to the
non-treated cells. Long-term exposure to compounds 0, 3, and 4
induced stronger reduction of migration index compared to
short-term exposure suggesting a time-dependent effect.
3.7. Expression of genes involved in invasion (COX-2 and MMP-9)
The rate of gene expression is directly connected with the levels
of protein synthesis important for regulation of migration/invasion
of breast cancer cells. The gene expression levels were determined
by qRT PCR method using the fluorescently labeled Syber Green
dye that generates the signal and quantifies the amount of
expressed mRNA (mRNA). The expression of the genes was deter-
mined only after long-term treatment (72 h).
The effects of synthesized derivatives 0, 3, and 4 in concentra-
tions of 1 mM and 10 mM on the change in expression of COX-2 genein MDA-MB-231 cells after long-term exposure (72 h) were shown
in Fig. 9A. The results show that the treatment with these three
derivatives at concentrations of 1 mM and 10 mM caused statisti-
cally significant reduction in COX-2 gene expression compared to
control cells.
Moreover, the results obtained from expression of MMP-9,
which plays an important role in the progression of breast cancer
cells (Duffy et al., 2000), indicate that tested compounds can affect
expression of the corresponding gene. The changes induced by
compounds 0, 3, and 4 in the level of MMP-9 gene expression com-
pared to control cells are shown in Fig. 9B. The results show that
long-term treatment with compounds 0, 3, and 4 at concentrations
of 1 mM and 10 mM induced a statistically significant reduction in
the expression of the MMP-9 gene compared to control cells.4. Discussion
Despite various new therapeutic approaches, chemotherapy
remains the most common form of breast cancer treatment, with
considerable limitations regarding excessive toxicity of frequently
used drugs and increasing resistance of cancer cells. Many studies
have implied the correlation between hydantoin structure and
Fig. 6. Effect of investigated compounds on NO production in the MDA-MB-231 cells during 24 h and 72 h exposure compared to non-treated control cell (100%). The cells
were treated with compounds 0, 3, and 4 at concentrations 1 mM (A) and 10 mM (B). The results are expressed as the mean ± SE from three independent experiments
performed in triplicate. (*p < 0.05 different concentrations of compound vs. control).
Fig. 7. Relative levels of iNOS mRNA expression following treatment with 1 mM and
10 mM of investigated compounds 0, 3, and 4 in MDA-MB-231 cells after 72 h. The
results are expressed as the mean ± SE from three independent experiments
performed in triplicate. (*p < 0.05 different concentrations of compound vs. control).
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are focused on the synthesis of novel hydantoin derivatives with
the aim of reinforcing their present antitumor potential (Jansen
et al., 2003, Kumar et al., 2017). Aromatic units at C5 position are
important structural property for interactions with biological
structures and studies have shown that 5-benzyliden-hydantoins
can function as 4-anilinokinazolin bioisosters already approved
for the treatment of lung cancer (Carmi et al., 2006, Cavazzoni
et al. al., 2008). The significant antiproliferative effect of certain
diazaspiro-bicyclo hydantoin derivatives on human leukemia cells
are also indicated (Kumar et al., 2009).
Tumor cells evade apoptosis, excessively proliferate and survive
under hypoxic conditions, acquiring the resistance to therapeuticagents (Liang et al., 2018). All examined hydantoin derivatives in
this study exerted antiproliferative activities in dose-dependent
manner until the concentration of 10 lM where the plateau was
reached. The compound 4 with chloro-substituent has shown the
strongest antiproliferative effect which is in accordance with liter-
ature data (Sekulić Djaković et al., 2015). All investigated deriva-
tives have shown satisfying biocompatibility (Obradović et al.,
2019), implying their safe use as potential drugs for treatment of
breast cancer. Apoptosis-inducing agents are expected to be effec-
tive antitumor drugs since apoptosis is an efficient protective
mechanism against tumor development that remove genetically
damaged cells before they undergo clonal expansion (Hassan
et al., 2014). The selected derivatives (0, 3 and 4) at both used con-
centrations (1 mM and 10 mM) induced statistically significant
increase of apoptosis rate and caspase activation in MDA-MB-231
cells in time-dependent manner. These results imply that some
of antitumor mechanisms of these derivatives is based on trigger-
ing of apoptosis and inhibiting the division of breast cancer cells.
Some previous studies have demonstrated that NO can induce
cell death by affecting apoptosis-related mitochondrial proteins
(Messmer et al., 1996, Snyder et al., 2009). The data acquired in
our study suggest that significant proapoptotic levels in MDA-
MB-231 cells could be mediated via increased NO production
induced by examined derivatives which could trigger the compo-
nents of intrinsic proapoptotic pathways. Besides, excessive gener-
ation of NO promotes formation of extremely aggressive
peroxynitrite (ONOO), which is one of the key molecules for
bimodal effects of NO in physiological and pathological conditions
(Pacher et al., 2007). Our results suggest that in this study investi-
gated hydantoin compounds are potent inducers of apoptosis of
breast cancer cell line which may correspond to NO-generating
potential of these molecules. Elevated levels of NO have also been
shown to inhibit metastasis in different tumor type which could
imply that NO generation has beneficial role in antitumor therapies
(Aranda et al., 2012). Our results indicate increase levels of NO in
Fig. 8. Effect of exposure to investigated compounds 0, 3, and 4 on migration index of MDA-MB-231 cells. The cells were treated at concentrations of 1 mM (A) and 10 (B) mM
during a 24 h and 72 h exposure. The results are expressed as the mean ± SE from three independent experiments performed in triplicate. (*p < 0.05 different concentrations
of compound vs. control).
Fig. 9. Relative levels of COX-2 (A) and MMP-9 (B) iRNA expression following
treatment with 1 mM and 10 mM investigated compounds 0, 3, and 4 in MDA-MB-
231 cells after 72 h. The results are expressed as the mean ± SE from three
independent experiments performed in triplicate. (*p < 0.05 different concentra-
tions of compound vs. control).
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One of the key genes involved in tumorigenesis is iNOS that gener-
ates NO in significant amounts in breast cancer cell (Choudhari
et al., 2013). A lot of antitumor agents have been aimed to trigger
iNOS gene expression in order to inhibit growth and induce apop-
tosis of metastatic tumor cells (Vannini et al., 2015). The hydantoinderivatives tested in our study have increased the expression level
for almost 100% compared to control levels, which explains the
high concentration of NO recorded in the study. These data indi-
cate that hydantoin derivatives are potential triggers of NO pro-
duction which could contribute to partly explain their
antiproliferative and proapoptotic properties. The results show
that long-term treatment (72 h) of MDA-MB-231 cells with
selected hydantoin derivatives (0, 3, and 4) caused statistically sig-
nificant increase of iNOS gene expression compared to non-treated
cells indicating that high concentration of NO may be caused by de
novo synthesis of these signal molecule.
The tested hydantoin derivatives in our study reduced the
migration capacity of MDA-MB-231 cells. Based on these data,
we proposed that one of the mechanisms by which these com-
pounds inhibit migration of human breast cancer cells is elevating
the bioavailability of NO. This molecule is involved in the regula-
tion of cell adhesion molecules, presumably the integrins, impor-
tant for cell motility (Roberts et al., 2008). Previously mentioned
elevation in NO production could indicate the role of NO in migra-
tion mechanisms of this cell type. Although the majority of studies
have reported invasion-promoting effects of NO in various cell
types, there are several studies which reported antimigratory and
antiproliferative effects of NO (Aranda et al., 2012). Reduction in
migration capacity could also be correlated with increased expres-
sion of the inducible isoform of cyclooxygenase, COX-2 gene
detected in the study. Majumder and colleagues have implied that
elevated COX-2 expression level had to promote effect on migra-
tion capacity of breast cancer cells (Majumder et al., 2016). In
our study reduced migration index could be caused by a decrease
in COX-2 expression level recorded in the treatments. The com-
pound 4 with chloro-substituent has shown the strongest reduc-
tion of the migratory potential of these cells. However, these
data suggest that tested hydantoin derivatives exert significant
antimigratory effects on breast cancer cells making them promis-
ing antitumor agents.
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microenvironment, are also important contributors to cancer pro-
gression, representing the crucial enzymes in tumor cell invasion
by leading to epithelial-mesenchymal transition. MMP-9 is
strongly associated with aggressive and metastatic breast cancer
(Mehner et al., 2014). MMP-9 and other MMPs as biomarkers of
breast cancer stage are used in the monitoring of therapeutic
responses on different individuals to estimate the efficiency of par-
ticular chemotherapeutic regimen (Said et al., 2014). The results of
our study have shown that long-term treatment (72 h) of MDA-
MB-231 cells with selected compounds (0, 3, and 4) induced statis-
tically significant reduction of expression level of the MMP-9 gene
compared to control cells, suggesting that these compounds may
reduce invasion capacity of MDA-MB-231 cells by downregulation
of MMP-9 expression.
Non-steroidal anti-inflammatory drugs NSAIDs are the most
used medicaments against inflammation, but besides their bene-
fits, serious side effects prompted the development for more selec-
tive COX-2 inhibitors such as Coxibs and NO-releasing NSAIDs
(Arun and Goss, 2004, Tołoczko-Iwaniuk et al., 2019). Inflamma-
tory molecules and factors involved in the wound healing process
are considered the key regulatory signals in numerous models of
tumorigenesis (Coussens and Werb, 2002, Philip et al., 2004).
COX-2 has been shown to represent an indicative link between
inflammation and progression of many types of cancer, including
breast cancer, and a lot of contemporary chemotherapies are aimed
at down-regulation of COX-2 activity (Koki et al., 2002, Hashemi
et al., 2019). Literature data suggest that COX-inhibitors can reduce
tumor invasion, representing reinforcement to standard cytotoxic
therapy (Liu et al., 2015). Certain hydantoin compounds such as
5,5-diarylhydantoin derivatives have shown more selective inhibi-
tion of COX-2 enzyme (Zarghi and Arfaei, 2011). Our results show
that compounds 0, 3, and 4 caused a statistically significant reduc-
tion in COX-2 gene expression compared to non-treated cells,
which additionally may promote one of the possible modes of their
antitumor action (Mehner et al., 2014). The comparative studies
with NSAID selective inhibitors are yet to be done, but we can sug-
gest that these novel hydantoin derivatives are promising agents in
reducing prostaglandin production in breast cancer cells MDA-MB-
231.5. Conclusions
The investigated hydantoin derivatives have shown significant
antitumor activity against MDA-MB-231 cells measured by differ-
ent parameters of cell physiology. Almost all tested compounds
exerted significant antiproliferative and proapoptotic effects in a
dose- and time-dependent manner as one of the most important
antitumor mechanisms. Also, these compounds have reduced cell
migration and invasion capacity, and shown significant selectivity
on proliferation index regarding non-malignant cells. Thus, our
study exhibited that investigated 3-(4-substituted benzyl)-5-iso
propyl-5-phenylhydantoin derivatives, owing to their pleiotropic
effects, had the potential for the treatment of breast cancer and
can be considered as a promising novel tumor therapy in humans,
whereby compounds 3 and 4 being particularly prominent and
which remains to be further explored.Acknowledgments
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Ušćumlić, G., Božić, B., Božić Nedeljković, B., 2019. Anti-Tumor Mechanisms of
Novel 3-(4-Substituted Benzyl)-5-Isopropil-5-Phenylhydantoin Derivatives on
Human Colon Cancer Cell Line. Anticancer. Agents. Med. Chem. doi:10.2174/
1871520619666190425180610
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